MOORESTOWN, N.J., July 24, 2017 -- Tabula Rasa HealthCare (NASDAQ:TRHC) Chairman and CEO, Calvin H. Knowlton, PhD, was the keynote speaker at The American Society for Automation in Pharmacy (ASAP) MidYear Conference in Palm Beach, Florida on June 22, 2017. Knowlton addressed the issue of adverse drug events (ADEs) and how technology can provide solutions.
“Regarding adverse drug events, unintentional misuse and overdose is looming,” said Dr. Knowlton. “As pharmacists, we must collaborate with our software friends to provide us with the medication risk mitigation tools we need to effect change and eliminate ADEs, which are often cited as the fourth leading cause of death. It is time to integrate the science that underlies our medication safety metrics into our pharmacy technology and systems.”
The conference highlighted technology’s role in pharmacy, particularly regarding ADEs, regulatory and dispensing requirements, cybersecurity in healthcare, specialty pharmacy and more.
Dr. Knowlton is the Founder, Chairman and CEO of Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by developing new Medication Risk Mitigation™ and medication decision support tools.
Dr. Knowlton has won numerous awards for his leadership in pharmacy, business, and philanthropy in his career of over 30 years, including the 2003 & 2013 Ernst and Young Entrepreneur of the Year Award, Greater Philadelphia Region, and the 2016 Philadelphia Technology CEO of the year. In 2015, Knowlton was awarded the Remington Honor Medal, pharmacy’s highest honor.
Contributing to his profession and the community, Dr. Knowlton has served as the national President for the American College of Apothecaries, President of the American Pharmacists Association (APhA) for two terms, and President of the American Pharmacists Association Foundation. He is the Board Chair of the Evergreens Continuing Care Retirement Community and serves on the Boards of Cooper Medical School of Rowan University. He recently finished terms on the Coriell Institute for Medical Research, St Christopher’s Hospital for Children in Philadelphia and the Settlement Music School in Philadelphia, PA.
Dr. Knowlton received his Pharmacy degree from Temple University, his Divinity degree from Princeton Theological Seminary, and his PhD in Pharmacoeconomics from the University of Maryland. He served as Professor and Department Chair for the University of the Sciences in Philadelphia in the 1990s. He has authored and co-authored textbooks, book chapters, and articles focused on the role and responsibility of pharmacists in the outcomes of patient-centered medication care.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s leading offering, and its cloud-based software applications, including EireneRx® and MedWise Advisor®, provide solutions for a range of payers, providers and other healthcare organizations. www.tabularasahealthcare.com
Contact Dianne Semingson [email protected] T: 215-870-0829


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



